Genetic variation in IL28B (IFNL3) and response to interferon‐alpha treatment in myeloproliferative neoplasms
- 25 January 2018
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 100 (5) , 419-425
Abstract
Objective: In myeloproliferative neoplasms (MPN), interferon‐alpha (IFN‐α) is an effective treatment with disease‐modifying properties but currently with no clear predictors of treatment outcome. Recent genomewide association studies in chronic hepatitis C have found a strong influence of genetic polymorphism near the IL28B (IFNL3) gene in response to IFN‐α treatment. In this study, we sought to evaluate the prognostic impact of IL28B rs12979860, rs8099917, and rs12980275 on IFN‐α treatment response in myeloproliferative neoplasms.Method: We retrospectively evaluated 100 patients with MPN treated with IFN‐α. The hematologic treatment response on IFN‐α was compared between patients and correlated with host genetic variations in IL28B. The genotypes of IL28B were determined by allelic discrimination assays.Results: The CC genotype of rs12979860 was found significantly associated with hematologic response in polycythemia vera (PV) with a complete response (CR) in 79% (CC) compared to 48% (non‐CC), (P = .036). No association between the genotypes and treatment response on hydroxyurea was found.Conclusion: These results imply an effect of IL28B genotype on the outcome of IFN‐α treatment in MPN.Keywords
This publication has 36 references indexed in Scilit:
- Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2bAmerican Journal of Hematology, 2014
- A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infectionJournal of Hepatology, 2014
- Type I and type III interferon-induced immune response: It's a matter of kinetics and magnitudeHepatology, 2013
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based RegimensClinical Pharmacology & Therapeutics, 2013
- The JAK-STAT Pathway at TwentyImmunity, 2012
- IFN-λsCurrent Opinion in Immunology, 2011
- Hepatitis C pharmacogenetics: State of the art in 2010Hepatology, 2010
- Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection†Hepatology, 2010
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009